Cargando…
A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis
Background: Cancer precision medicine is an effective strategy to fight cancers by bridging genomics and drug discovery to provide specific treatment for patients with different genetic characteristics. Although some public databases and modelling frameworks have been developed through studies on dr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878337/ https://www.ncbi.nlm.nih.gov/pubmed/36713829 http://dx.doi.org/10.3389/fphar.2023.1085765 |
_version_ | 1784878468624809984 |
---|---|
author | Liu, Yijun Song, Fuhu Li, Zhi Chen, Liang Xu, Ying Sun, Huiyan Chang, Yi |
author_facet | Liu, Yijun Song, Fuhu Li, Zhi Chen, Liang Xu, Ying Sun, Huiyan Chang, Yi |
author_sort | Liu, Yijun |
collection | PubMed |
description | Background: Cancer precision medicine is an effective strategy to fight cancers by bridging genomics and drug discovery to provide specific treatment for patients with different genetic characteristics. Although some public databases and modelling frameworks have been developed through studies on drug response, most of them only considered the ramifications of the drug on the cell line and the effects on the patient still require a huge amount of work to integrate data from various databases and calculations, especially concerning precision treatment. Furthermore, not only efficacy but also the adverse effects of drugs on patients should be taken into account during cancer treatment. However, the adverse effects as essential indicators of drug safety assessment are always neglected. Method: A holistic estimation explores various drugs’ efficacy levels by calculating their potency both in reversing and enhancing cancer-associated gene expression change. And a method for bridging the gap between cell culture and living tissue estimates the effectiveness of a drug on individual patients through the mappings of various cell lines to each person according to their genetic mutation similarities. Result: We predicted the efficacy of FDA-recommended drugs, taking into account both efficacy and toxicity, and obtained consistent results. We also provided an intuitive and easy-to-use web server called DBPOM (http://www.dbpom.net/, a comprehensive database of pharmaco-omics for cancer precision medicine), which not only integrates the above methods but also provides calculation results on more than 10,000 small molecule compounds and drugs. As a one-stop web server, clinicians and drug researchers can also analyze the overall effect of a drug or a drug combination on cancer patients as well as the biological functions that they target. DBPOM is now public, free to use with no login requirement, and contains all the data and code. Conclusion: Both the positive and negative effects of drugs during precision treatment are essential for practical application of drugs. DBPOM based on the two effects will become a vital resource and analysis platform for drug development, drug mechanism studies and the discovery of new therapies. |
format | Online Article Text |
id | pubmed-9878337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98783372023-01-27 A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis Liu, Yijun Song, Fuhu Li, Zhi Chen, Liang Xu, Ying Sun, Huiyan Chang, Yi Front Pharmacol Pharmacology Background: Cancer precision medicine is an effective strategy to fight cancers by bridging genomics and drug discovery to provide specific treatment for patients with different genetic characteristics. Although some public databases and modelling frameworks have been developed through studies on drug response, most of them only considered the ramifications of the drug on the cell line and the effects on the patient still require a huge amount of work to integrate data from various databases and calculations, especially concerning precision treatment. Furthermore, not only efficacy but also the adverse effects of drugs on patients should be taken into account during cancer treatment. However, the adverse effects as essential indicators of drug safety assessment are always neglected. Method: A holistic estimation explores various drugs’ efficacy levels by calculating their potency both in reversing and enhancing cancer-associated gene expression change. And a method for bridging the gap between cell culture and living tissue estimates the effectiveness of a drug on individual patients through the mappings of various cell lines to each person according to their genetic mutation similarities. Result: We predicted the efficacy of FDA-recommended drugs, taking into account both efficacy and toxicity, and obtained consistent results. We also provided an intuitive and easy-to-use web server called DBPOM (http://www.dbpom.net/, a comprehensive database of pharmaco-omics for cancer precision medicine), which not only integrates the above methods but also provides calculation results on more than 10,000 small molecule compounds and drugs. As a one-stop web server, clinicians and drug researchers can also analyze the overall effect of a drug or a drug combination on cancer patients as well as the biological functions that they target. DBPOM is now public, free to use with no login requirement, and contains all the data and code. Conclusion: Both the positive and negative effects of drugs during precision treatment are essential for practical application of drugs. DBPOM based on the two effects will become a vital resource and analysis platform for drug development, drug mechanism studies and the discovery of new therapies. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9878337/ /pubmed/36713829 http://dx.doi.org/10.3389/fphar.2023.1085765 Text en Copyright © 2023 Liu, Song, Li, Chen, Xu, Sun and Chang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Liu, Yijun Song, Fuhu Li, Zhi Chen, Liang Xu, Ying Sun, Huiyan Chang, Yi A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
title | A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
title_full | A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
title_fullStr | A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
title_full_unstemmed | A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
title_short | A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
title_sort | comprehensive tool for tumor precision medicine with pharmaco-omics data analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878337/ https://www.ncbi.nlm.nih.gov/pubmed/36713829 http://dx.doi.org/10.3389/fphar.2023.1085765 |
work_keys_str_mv | AT liuyijun acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT songfuhu acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT lizhi acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT chenliang acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT xuying acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT sunhuiyan acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT changyi acomprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT liuyijun comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT songfuhu comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT lizhi comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT chenliang comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT xuying comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT sunhuiyan comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis AT changyi comprehensivetoolfortumorprecisionmedicinewithpharmacoomicsdataanalysis |